LeMaitre Vascular, Inc. Provides Earnings Guidance for the Second Quarter and Full Year 2022
April 28, 2022 at 04:20 pm EDT
Share
LeMaitre Vascular, Inc. provided earnings guidance for the second quarter and full year 2022. For the second quarter, the company expects sales of $40.1 million to $42.1 million (Mid: $41.1 million, +1%, +5% Org.); Operating Income of $5.7 million to $7.0 million (Mid: $6.4 million, -43%); and EPS of $0.20 - $0.25 (Mid: $0.23, -43%).
For the full year, the company expects sales of $160.0 million to $164.0 million (Mid: $162.0 million, 5%, +8% Org.); Operating Income of $31.4 million to $34.0 million (Mid: $32.7 million, -10%); and EPS of $1.10 to $1.20 (Mid: $1.15, -8%). Since the Company's February 24th guidance, full year 2022 sales guidance was lowered by $2.0 million due to a $3.0 million negative impact from the stronger U.S. dollar. 2022 organic sales growth guidance is up slightly to 8.2%. Changes in foreign exchanges rates since the Company's February 24th guidance also reduced 2022 full year operating income guidance by $1.6 million.
LeMaitre Vascular, Inc. is a provider of devices, implants, and services for the treatment of peripheral vascular disease. The Company develops, manufactures, and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. Its portfolio of product lines is primarily used to treat vascular disease, of which most are used in open vascular surgery and dialysis access. It also offers human vascular and cardiac tissue cryopreservation services. Its principal product lines include anastomotic clips, biologic vascular and dialysis grafts, biologic vascular and cardiac patches, carotid shunts, embolectomy catheters, occlusion catheters, radiopaque marking tape, synthetic vascular and dialysis grafts, and valvulotomes. The Companyâs principal biologic offerings include vascular and cardiac patches as well as vascular and dialysis grafts. The Company sells its products and services primarily through a direct sales force.
LEMAITRE VASCULAR, INC. 
